2 Minute Medicine

1. The objective response rate for trastuzumab deruxtecan was 29.4%. 2. Treatment-emergent adverse event grade 3 or higher was seen in 51% of patients. Evidence Rating Level: 2 (Good) Study...

1. Although capecitabine or XELOX did not improve overall survival when compared to PF, efficacy was comparable suggesting single-agent capecitabine as a potential alternative to combination chemotherapy for select patients....

1. Progression-free survival at 24 months was higher in the pembrolizumab versus placebo-controlled group. 2. The pembrolizumab-chemoradiotherapy group reported slightly higher rates of grade 3 or higher adverse events compared...

Association of ultra-processed food consumption with all cause and cause specific mortality: population based cohort study 1. Consumption of ultra-processed foods was associated with modestly higher all-cause mortality, with meat/poultry/seafood...